EQS-Adhoc: APONTIS PHARMA AG: Merger Squeeze-out Cash Compensation Determined at EUR 10.40
|
EQS-Ad-hoc: APONTIS PHARMA AG / Key word(s): Squeeze Out Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014 Zentiva AG currently holds approximately 91.95% and, after deducting the number of treasury shares pursuant to section 62 para. 1 sentence 2 UmwG, approximately 93.83% of APONTIS PHARMA AG’s share capital and is therefore the major shareholder of APONTIS PHARMA AG as defined by section 62 para. 5 UmwG. Zentiva AG has determined the amount of the cash compensation to be EUR 10.40 per APONTIS PHARMA AG share. The court-appointed expert auditor has already indicated that, from a current standpoint, it will confirm the cash compensation to be adequate. The conclusion and notarization of the merger agreement between APONTIS PHARMA AG and Zentiva AG will take place today. At APONTIS PHARMA AG’s annual general meeting, which is expected to be held on 29 July 2025, a resolution will be adopted on transferring APONTIS PHARMA AG minority shareholders’ shares to Zentiva AG against a cash compensation of EUR 10.40 per share. The effectiveness of the merger squeeze-out is still subject to the approval by the APONTIS PHARMA AG annual general meeting and the registration of both the transfer resolution and the merger in the commercial register at the seat of APONTIS PHARMA AG, as well as the registration of the merger in the commercial register at the seat of Zentiva AG. Investor Relations CROSS ALLIANCE communication GmbH End of Inside Information
13-Jun-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | APONTIS PHARMA AG |
| Rolf-Schwarz-Schütte-Platz 1 | |
| 40789 Monheim am Rhein | |
| Germany | |
| E-mail: | ir@apontis-pharma.de |
| Internet: | https://apontis-pharma.de/ |
| ISIN: | DE000A3CMGM5 |
| WKN: | A3CMGM |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2154370 |
| End of Announcement | EQS News Service |
|
|
2154370 13-Jun-2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 40,04 | 39,24 | 51,18 | 55,73 | 36,96 | 48,47 | 56,40 | |
| EBITDA1,2 | -1,72 | 1,00 | 2,36 | 5,57 | -13,28 | 3,48 | 4,50 | |
| EBITDA-Margin3 | -4,30 | 2,55 | 4,61 | 10,00 | -35,93 | 7,18 | 7,98 | |
| EBIT1,4 | -2,29 | -0,66 | 0,62 | 3,77 | -15,16 | 1,24 | 2,40 | |
| EBIT-Margin5 | -5,72 | -1,68 | 1,21 | 6,77 | -41,02 | 2,56 | 4,26 | |
| Net Profit (Loss)1 | -2,39 | -1,18 | -0,75 | 2,69 | -12,68 | 0,75 | 1,45 | |
| Net-Margin6 | -5,97 | -3,01 | -1,47 | 4,83 | -34,31 | 1,55 | 2,57 | |
| Cashflow1,7 | -0,24 | 1,45 | 3,43 | 11,02 | -12,60 | -2,90 | 3,10 | |
| Earnings per share8 | -0,28 | -0,14 | -0,09 | 0,32 | -1,49 | 0,09 | 0,17 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: RSM Ebner Stolz
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Apontis Pharma | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A3CMGM | DE000A3CMGM5 | AG | 92,65 Mio € | 11.05.2021 | Verkaufen | 9F383VCV+Q2 |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 27,95 | 25,63 | 1,09 | 55,90 | 2,99 | -31,95 | 1,91 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 29.07.2025 | 15.05.2025 | 09.08.2024 | 07.11.2024 | 31.03.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +0,84% | -0,39% | +9,00% | +11,22% | -42,63% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
